Why Is AstraZeneca Stock Trading Lower On Tuesday?
Why Is AstraZeneca Stock Trading Lower On Tuesday?
In the pre-specified subgroup of patients with nonsquamous NSCLC, datopotamab deruxtecan showed a clinically meaningful improvement in OS compared to docetaxel, the current standard of care chemotherapy.On Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population in the TROPION-Lung01 phase 3 trial.
阿斯利康公司（納斯達克股票代碼：AZN）週二表示，在Tropion-Lung01三期試驗的總試驗人群中，存活結果未達到統計學意義。
Topline overall survival (OS) results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients treated with at least one prior line of therapy.
Tropion-Lung01 3期試驗的最高總存活率（OS）結果，該試驗之前達到了無進展存活率（PFS）的雙重主要終點，與多西他賽相比，在接受過至少一種先前療法治療的局部晚期或轉移性非小細胞肺癌（NSCLC）患者中，與多西他賽相比，在數字上更受青睞。
Also Read: AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion.
另請閱讀： 阿斯利康的目標是通過管道擴張，到2030年實現800億美元的總收入。
In the pre-specified subgroup of patients with nonsquamous NSCLC, datopotamab deruxtecan showed a clinically meaningful improvement in OS compared to docetaxel, the current standard of care chemotherapy.
在預先指定的非鱗狀非小細胞肺癌患者亞組中，與目前的護理化療標準多西他賽相比，datopotamab deruxtecan顯示出具有臨床意義的改善。
Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate discovered by Daiichi Sankyo (OTC:DSKYF) (OTC:DSNKY) and being jointly developed by Daiichi Sankyo and AstraZeneca.
Datopotamab deruxtecan 是由第一三共公司（OTC: DSKYF）（場外交易代碼：DSKYF）（場外交易代碼：DSNKY）發現的一種專門設計的 TROP2 導向 dxD 抗體藥物偶聯物，由第一三共和阿斯利康共同開發。
The final analysis of OS builds on the PFS results presented at the European Society for Medical Oncology 2023 Congress, which showed that datopotamab deruxtecan demonstrated a statistically significant improvement in PFS in the overall trial population and a clinically meaningful PFS benefit in patients with nonsquamous NSCLC.
操作系統的最終分析建立在歐洲腫瘤內科學會2023年大會上公佈的PFS結果基礎上，該結果顯示，達託泊他單德魯替康在整個試驗人群中顯示出具有統計學意義的顯著改善，非鱗狀非小細胞肺癌患者的PFS益處具有臨床意義。
The safety profile of datopotamab deruxtecan in TROPION-Lung01 was consistent with the previous analysis, including fewer dose reductions or discontinuations due to adverse events compared to docetaxel and with no new safety concerns identified. No new interstitial lung disease events of any grade were adjudicated as drug-related.
Datopotamab deruxtecan在Tropion-Lung01中的安全性概況與先前的分析一致，包括與多西他賽相比，由於不良事件導致的劑量減少或停藥較少，也沒有發現新的安全問題。沒有任何級別的新間質性肺病事件被裁定爲與藥物有關。
"Datopotamab deruxtecan is the only investigational therapy to show a clinically meaningful survival improvement in patients with previously treated nonsquamous non-small cell lung cancer versus docetaxel, which has long been unsurpassed in this post-targeted treatment and post-immunotherapy setting," said Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca.
阿斯利康腫瘤學研發執行副總裁蘇珊·加爾佈雷思說：“與多西他賽相比，Datopotamab deruxtecan是唯一一種顯示先前接受過治療的非鱗狀非小細胞肺癌患者存活率有臨床意義改善的在研療法，多西他賽在這種靶向後治療和免疫後治療環境中一直是無與倫比的。”
TROPION-Lung01 enrolled approximately 600 patients.
Tropion-Lung01 招收了大約 600 名患者。
Price Action: AZN shares were down 2.40% at $76.66 at the last check on Tuesday.
價格走勢：在週二的最後一次支票中，AZN股價下跌2.40％，至76.66美元。
Image by Robert Way via Shutterstock
圖片由 Robert Way 通過 Shutterstock 提供
譯文內容由第三人軟體翻譯。
